Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9594 posts found.

ViroCell Biologics and AvenCell Therapeutics partner to accelerate allogeneic CAR-T therapy development

July 29, 2025 Contract Manufacturing, Manufacturing Services, Mergers and Acquisitions, Research and Development AvenCell Therapeutics, CAR-T therapy, Contract Development Manufacturing Organisation, Good Manufacturing Practice, Immunology, Oncology, ViroCell Biologics, autoimmune diseases, blood cancer

ViroCell Biologics has announced a new manufacturing collaboration with AvenCell Therapeutics to produce a high-yield retroviral vector supporting the clinical …
News

Relief Therapeutics to merge with NeuroX to create AI-driven neurohealth company

July 29, 2025 Mergers and Acquisitions, Research and Development AI, Corporate, MindMaze, Neurology, Relief Therapeutics, neurological conditions

Relief Therapeutics has announced that it will combine with NeuroX Group, the successor to digital neurotherapeutics company MindMaze. The transaction …
News

Universal Quantum partners with Open Quantum Institute to tackle endometriosis with new technology

July 29, 2025 Medical Communications, Research and Development Open Quantum Institute, Pain, Reproductive health, UN Sustainable Development Goals, United Nations, Universal Quantum, endometriosis, women's health

Based in Brighton, UK, Universal Quantum has joined the Open Quantum Institute (OQI) to explore how quantum computing could revolutionise …
News
Prescriptions image

Mental health medicine use in England reaches record high, NHSBSA report reveals

July 29, 2025 Manufacturing and Production, Medical Communications, Research and Development ADHD, COVID-19, NHS Business Services Authority, Psychiatry, antidepressants, antipsychotics, anxiolytics, barbiturate, dementia, hypnotics, mental health

According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions in England have reached their …
News

Bristol Myers Squibb appoints Cristian Massacesi as chief medical officer and head of development

July 28, 2025 Research and Development Bristol Myer Squibb, Corporate, Executive Leadership Team, Head of Development, chief medical officer, executive vice president

Bristol Myers Squibb (BMS) has announced the appointment of Cristian Massacesi as executive vice president, chief medical officer, and head …
Appointment

Neuraxpharm appoints Avendran Naidu as head of commercial upon launch of Australian affiliate

July 28, 2025 Manufacturing and Production, Research and Development Neuraxpharm, Neuraxpharm Australia, Neurology, central nervous system, multiple sclerosis

Neuraxpharm Group has announced the launch of Neuraxpharm Australia, furthering its global expansion beyond Europe and into key international markets. …
Appointment
mental-health-3332122_960_720

Seaport Therapeutics doses first patient in trial of GlyphAllo for depression

July 25, 2025 Research and Development Psychiatry, Seaport Therapeutics, clinical trial, major depressive disorder, mental health, neuropsychiatric conditions

Seaport Therapeutics has dosed its first patient in its phase 2b BUOY-1 study of GlyphAllo (SPT-300), an oral prodrug of …
News

Cube Biotech appoints Michael Bencak as new CEO amid global expansion plans

July 25, 2025 Mergers and Acquisitions, Research and Development CEO, Corporate, Cube Biotech, IBA Lifescience, archimed, executive chairman

Cube Biotech has announced a leadership transition as the company continues its trajectory of global growth and innovation in protein …
Appointment

PureTech Health appoints interim CEO Robert Lyne

July 24, 2025 Research and Development Corporate, PureTech Health, board of directors, chief portfolio officer, interim CEO

PureTech Health has announced the departure of chief executive officer (CEO) Bharatt Chowrira, who has stepped down from his role …
Appointment
eyeimagenotext-1

OKYO Pharma reports promising phase 2 results for urcosimod in neuropathic corneal pain

July 24, 2025 Research and Development OKYO Pharma, Opthalmology, clinical trial, neuropathic corneal pain, ocular pain

OKYO Pharma has announced positive results from its phase 2 trial of urcosimod (formerly OK-101) in neuropathic corneal pain (NCP), …
News
handshake-1910702_960_720

Evestia Clinical and Atlantic Research Group merge to create global specialist CRO

July 23, 2025 Clinical Trial Services, Mergers and Acquisitions, Research and Development Atlantic Research Group, Corporate, Evestia Clinical, clinical trials, contract research organisation

UK-based Evestia Clinical will merge with US-based Atlantic Research Group (ARG), forming a leading independent global contract research organisation (CRO) …
News

MetP Pharma releases positive data on intranasal semaglutide administration

July 22, 2025 Research and Development Diabetes, MetP Pharma, Neurology, Obesity, central nervous system, diabetes, obesity, peptides, semaglutide

MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering neuroactive peptides, particularly semaglutide, directly …
News

Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis

July 21, 2025 Medical Communications, Mergers and Acquisitions, Research and Development Boehringer Ingelheim, Dermatology, LEO Pharma, Spevigo, generalised pustular psoriasis, partnership, skin disease

Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a treatment for generalised pustular psoriasis …
News

LDC strengthens healthcare focus with appointment of Amit Thaper as investment director

July 21, 2025 Business Services, Industry Associations, Research and Development Corporate, Inicio Health, Investment Director, LDC, RDi

LDC, the private equity arm of Lloyds Banking Group, has strengthened its healthcare expertise with the appointment of Amit Thaper …
Appointment
Brain image

Johnson & Johnson submits FDA application for Caplyta to prevent schizophrenia relapse

July 18, 2025 Medical Communications, Research and Development CAPLYTA, Johnson & Johnson, Neurology, US Food and Drug Administration, neuroscience, new drug application, schizophrenia

Johnson & Johnson has submitted a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Caplyta …
News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026